Key facts
- This page summarizes Danielle Watson's Form 3 filing for Heart Test Laboratories, Inc. (HSCS).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2022, 13:31.
Danielle Watson - 14 Jun 2022 Form 3 Insider Report for Heart Test Laboratories, Inc. (HSCS)
- Reporting relationship
- Vice President and Chief Financial Officer
- Issuer ticker
- HSCS
- Reported as of
- 14 Jun 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Jul 2022, 13:31:37 UTC
- Next SEC filing
- 22 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Danielle Watson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Danielle Watson filed Form 3 for Heart Test Laboratories, Inc. (HSCS) on 06 Jul 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HSCS
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 14 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,545
- Exercise price
- $3.47
- Footnotes
- F1
HSCS
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 14 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,545
- Exercise price
- $3.47
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option becomes exercisable in multiple installments upon the passing of certain periods. The first installment of approximately 33% of the option vests and becomes exercisable on October 31, 2022, and the remainder vests and becomes exercisable in equal instalments over the following eight fiscal quarters.
Footnote F2
The entire option has become fully-vested and may be exercised at any time at the Holder's election.
SEC remarks
Vice President and Chief Financial Officer